急性早幼粒细胞白血病
生物
三氧化二砷
交易激励
癌症研究
白血病
维甲酸
染色质免疫沉淀
髓系白血病
免疫系统
心理压抑
人口
早幼粒细胞白血病蛋白
维甲酸
免疫学
分子生物学
转录因子
发起人
基因表达
细胞培养
生物化学
医学
细胞凋亡
基因
遗传学
环境卫生
作者
X-W Yang,Ping Wang,Junqi Liu,Hui Zhang,W-D Xi,X-H Jia,K-K Wang
出处
期刊:Oncogene
[Springer Nature]
日期:2013-06-17
卷期号:33 (21): 2700-2708
被引量:34
摘要
Recognition and elimination of malignant cells by cytotoxic T lymphocytes depends on antigenic peptides generated by proteasomes. It has been established that impairment of the immunoproteasome subunits, that is, PSMB8, PSMB9 and PSMB10 (PSMBs), is critical for malignant cells to escape immune recognition. We report here the regulatory mechanism of the repression of PU.1-dependent activation of PSMBs by PML/RARα in the pathogenesis of acute promyelocytic leukemia (APL) and the unidentified function of all-trans retinoic acid (ATRA) as an immunomodulator in the treatment of APL. Chromatin immunoprecipitation and luciferase reporter assays showed that PU.1 directly bound to and coordinately transactivated the promoters of PSMBs, indicating that PSMBs were transcriptional targets of PU.1 and PU.1 regulated their basal expression. Analysis of expression profiling data from a large population of acute myeloid leukemia (AML) patients revealed that the expression levels of PSMBs were significantly lower in APL patients than in non-APL AML patients. Further evidence demonstrated that the decrease in their expression was achieved through PML/RARα-mediated repression of both PU.1-dependent transactivation and PU.1 expression. Moreover, ATRA but not arsenic trioxide induced the expression of PSMBs in APL cells, indicating that ATRA treatment might activate the antigen-processing/presentation machinery. Finally, the above observations were confirmed in primary APL samples. Collectively, our data demonstrate that PML/RARα suppresses PU.1-dependent activation of the immunosubunits, which may facilitate the escape of APL cells from immune surveillance in leukemia development, and ATRA treatment is able to reactivate their expression, which would promote more efficient T-cell-mediated recognition in the treatment.
科研通智能强力驱动
Strongly Powered by AbleSci AI